scholarly journals Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis

2009 ◽  
Vol 61 (3) ◽  
pp. 386-392 ◽  
Author(s):  
José Luis FerNández-Sueiro ◽  
Alfredo Willisch ◽  
Sonia Pértega- Díaz ◽  
José Antonio Pinto Tasende ◽  
Carlos Fernández-Lopez ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Spinal Mobility ◽  
Spinal Involvement

scholarly journals Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

2018 ◽  
Vol 45 (10) ◽  
pp. 1389-1396 ◽  
Author(s):  
Philip J. Mease ◽  
Jacqueline B. Palmer ◽  
Mei Liu ◽  
Arthur Kavanaugh ◽  
Renganayaki Pandurengan ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Activity Index ◽  
Health Assessment ◽  
Disease Activity Index ◽  
Severe Psoriasis ◽  
Spinal Involvement ◽  
Patient Reported ◽  
Axial Involvement

Objective.We analyzed the characteristics of patients with psoriatic arthritis (PsA) with and without axial involvement in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry.Methods.All patients were included who had PsA and data on axial involvement, defined as physician-reported presence of spinal involvement at enrollment, and/or radiograph or magnetic resonance imaging showing sacroiliitis. Demographics, clinical measures, patient-reported outcomes, and treatment characteristics were assessed at enrollment.Results.Of 1530 patients with PsA, 192 (12.5%) had axial involvement and 1338 (87.5%) did not. Subgroups were similar in sex, race, body mass index, disease duration, presence of dactylitis, and prevalence of most comorbidities. However, patients with axial involvement were younger and more likely to have enthesitis, a history of depression, and more frequently used biologics at enrollment. They were also more likely to have moderate/severe psoriasis (body surface area ≥ 3%, 42.5% vs 31.5%) and significantly worse disease as measured by a lower prevalence of minimal disease activity (30.1% vs 46.2%) and higher nail psoriasis scores [visual analog scale (VAS) 11.4 vs 6.5], enthesitis counts (5.1 vs 3.4), Bath Ankylosing Spondylitis Disease Activity Index (4.7 vs 3.5) scores, Bath Ankylosing Spondylitis Functional Index (3.8 vs 2.5) scores, C-reactive protein levels (4.1 vs 2.4 mg/l), and scores for physical function (Health Assessment Questionnaire, 0.9 vs 0.6), pain (VAS, 47.7 vs 36.2), and fatigue (VAS, 50.2 vs 38.6).Conclusion.Presence of axial involvement was associated with a higher likelihood of moderate/severe psoriasis, with higher disease activity and greater effect on quality of life. These findings highlight the importance of monitoring patients with PsA for signs of axial symptoms or spinal involvement.

scholarly journals AB0825 TIME-COURSE CHANGE IN AXIAL MOBILITY IN PSORIATIC ARTHRITIS PATIENTS UNDER bDMARD

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1716-1717
Author(s):  
M. Rato ◽  
F. Pinheiro ◽  
S. Garcia ◽  
B. M. Fernandes ◽  
S. Ganhão ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Physical Function ◽  
Time Course ◽  
Functional Limitation ◽  
Spinal Mobility ◽  
University Hospital ◽  
The Impact

Background:Spinal mobility is assessed frequently in patients with psoriatic arthritis (PsA) usingBath Ankylosing Spondylitis Metrology Index(BASMI) to provide baseline measurement, monitor changes over time and to assess the impact of clinical interventions. BASMI comprises 4 measures of spinal mobility (cervical rotation, tragus-to-wall distance, modified Schober’s test and lumbar lateral flexion) and one hip mobility measurement (intermalleolar distance).Objectives:The aim of this study is to investigate the time-course change of BASMI in PsA patients after 6 months ofBiologic Disease-modifying Antirheumatic Drug(bDMARD) therapy. The authors also pretend to evaluated, at baseline and after 6 months of treatment, the association between BASMI, disease activity scores and physical function.Methods:An observational retrospective study was performed in patients with PsA under bDMARD followed in the Rheumatology department of a tertiary university hospital. Were included patients treated with only one bDMARD. Demographic and clinical data were collected from the Rheumatic Diseases Portuguese Register. For spinal mobility calculation BASMI was used. Disease activity was evaluated withAnkylosing Spondylitis Disease Activity Score(ASDAS) andBath Ankylosing Spondylitis Activity Index(BASDAI). Physical function was assessed withBath Functional Index(BASFI). The variation of BASMI, ASDAS, BASDAI and BASFI was calculated as the difference between values registered at 6 months and at baseline and presented as Δ. Correlations between ΔBASMI, ΔASDAS and ΔBASFI was calculated using Pearson test.Results:A total of 55 patients were included. Thirty patients were males (54.5%). The mean age at diagnosis was 44.6 ± 12.6 years and the median disease duration at start of bDMARD was 5.4 years (min: 0.30; max: 25.5). In total, 19 (34.5%) patients had predominant axial involvement, 36 (65.5%) peripheric and 36 (65.5%) enthesopathic. Almost all patients fulfilled the CASPAR criteria for PsA (n=50, 90.9%). According to ASDAS criteria, at the baseline 20 patients (36.4%) had high disease activity and 34 (61,8%) very high. The most used bDMARD was etanercept (n=21, 38,3%) followed by golimumab (n=19, 34.5%) and adalimumab (n=8, 14.5%). Three patients were treated with infliximab, two with certolizumab and other two with secukinumab. Forty-one patients (75.9%) were concomitantly treated with conventional synthetic DMARDs. Axial PsA patients had more limitations in spinal mobility (BASMI mean 4.5 ± 1.5) and more functional limitation (BASFI mean 6.8±1.9) than patients with predominant peripheric involvement (BASMI mean 3.3± 1.2, p=0.004; BASFI mean 5.4±3, p=0,0048). Statistically significant differences in ASDAS and BASDAI in these two groups were not observed (p=0.332 and p=0.605, respectively). For all patients, BASMI did not vary significantly (p=0.691) at baseline (mean 3.7± 1.4) and after 6 months (mean 3.8±1.3) of treatment. Although the ΔBASMI for etanercept was negative (mean -0.12±0.9) and for golimumab positive (0.14±0.8), it was not statistically significant. At baseline there is a significant positive association between BASMI and ASDAS (r=0.435, p=0.001), BASMI and BASDAI (r=0.567, p<0.001) and BASMI and BASFI (r=0.510, p<0.001). However, there was not a statistically significant association between ΔBASMI and: ΔASDAS, ΔBASDAI and ΔBASFI (r=0.158; p=0.269, r=0.019; p=0.096 and r=0.121; p=0.397, respectively).Conclusion:In PsA patients treated with bDMARDs, at least in short-term follow-up, BASMI does not improve with time. Changes in BASMI did not correlate with changes in activity disease and in functional outcome. Studies with longer follow-up and with more patients are needed to better evaluate these associations.Disclosure of Interests:Maria Rato: None declared, Filipe Pinheiro: None declared, Salomé Garcia: None declared, Bruno Miguel Fernandes: None declared, Sara Ganhão: None declared, Rita Gaio: None declared, Miguel Bernardes Speakers bureau: Abbvie, Amgen, Biogen, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Novartis, Alexandra Bernardo: None declared, Lúcia Costa: None declared

FRI0334 COMPARATIVE ASSESSMENT OF COMORBIDITY IN ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS WITH AND WITHOUT SPINAL INVOLVEMENT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 759-760
Author(s):  
A. Dadalova ◽  
E. Vasilenko ◽  
R. Samigullina ◽  
V. Mazurov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Gastrointestinal Tract ◽  
Axial Spondyloarthritis ◽  
Chronic Inflammatory Disease ◽  
Comorbid Conditions ◽  
Spinal Involvement ◽  
Asas Criteria

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease is associated with a lot of comorbidities, especially the diseases of cardiovascular system. [1] These diseases not only lead to a decrease in the quality of life and disability of patients, but also to a decrease in life expectancy in comparison with the general population. [2]Objectives:The goal of study is to identify the most significant and common comorbid conditions in patients with axial spondylitis and compare their prevalence in three groups: in patients with ankylosing spondylitis, patients with psoriatic arthritis with and without spinal involvement.Methods:The study included 140 patients with a reliable diagnosis of axSpA (ASAS criteria, 2009), which were subsequently divided into three groups: patients with ankylosing spondylitis, patients with psoriatic arthritis with and without spinal involvement. In all patients comorbid conditions was evaluated.Results:The most common comorbid conditions among patients with axSpA were overweight (65%), included obesity (44%), hypertension (45%), diabetes and prediabetes (31,4%), dyslipidemia (23,6%), coronary heart disease (9,3%), diseases of the gastrointestinal tract (38,6%). Then we analyzed the prevalence of these comorbid pathologies in three groups.The characteristics of the groups are presented in Table 1.Table 1.Characteristic of the patients with axial spondyloarthritis (n=140).ResultsIndicatorankylosing spondylitispsoriatic arthritis without spinal involvementpsoriatic arthritis with spinal involvementQuantity484745Male, n (%)30 (62,5)19 (40,4)25 (55,6)Age, years (mean±SD)41,6 ± 11,053,32 ± 11,046,9 ± 10,4Disease duration, years (mean±SD)14,8 ± 9,417,1 ± 8,613,6 ± 5,9BMI, kg/m2(mean±SD)25,0 ± 4,229,2 ± 5,029,3 ± 4,0Overweight, n (%)18 (37,5)35 (74,5)38 (84,4)Included obesity, n (%)7 (14,6)19 (40,4)18 (40)Hypertension, n (%)11 (22,9)32 (68,1)21 (46,7)Diabetes and prediabetes, n (%)4 (8,3)13 (27,7)8 (17,8)Dyslipidemia, n (%)4 (8,3)13 (27,7)16 (35,6)Coronary heart disease, n (%)2 (4,2)8 (17,0)3 (6,7)Diseases of the gastrointestinal tract, n (%)19 (39,6)20 (42,6)16 (35,6)Conclusion:The prevalence of diseases of the gastrointestinal tract is approximately equal in all three groups, which is probably due to the use of non-steroidal anti-inflammatory drugs and glucocorticoids. The prevalence of the other pathology presented is significantly higher in the groups of psoriatic arthritis and does not significantly differ depending on the involvement of the spine in the pathological process.Due to the high prevalence of cardiovascular disease among patients with psoriatic arthritis, careful monitoring and timely administration of therapy is necessary.References:[1]Zhao SS, et al. Rheumatology (Oxford). 2019 Dec 22. pii: kez573. doi: 10.1093/rheumatology/kez573[2]Sinnathurai P, et al. Intern Med J. 2018 Nov;48(11):1360-1368. doi: 10.1111/imj.14046.Disclosure of Interests:None declared

Health-Related Quality of Life in Patients with Ankylosing Spondylitis: Relationship with Disease-Related Variables

2020 ◽  
Vol 16 (4) ◽  
pp. 311-318 ◽  
Author(s):  
Gehan Elolemy ◽  
Ahmed Aboughanima ◽  
Sahar Ganeb ◽  
Haytham Elziat
Keyword(s):  
Quality Of Life ◽  
Ankylosing Spondylitis ◽  
Physical Health ◽  
Disease Activity ◽  
Functional Status ◽  
Spinal Mobility ◽  
Peripheral Arthritis ◽  
Radiographic Severity ◽  
Sf 36

Background: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease leading to functional limitations and subsequently impaired quality of life (QoL). Despite the fact that QoL was recognized as a significant perception, it was excluded from the core domains (defined by the Assessment of Spondyloarthritis International Society), because of ambiguity of measurement choice. Aim: To assess QoL in patients with AS using a generic; Short Form-36 (SF-36) and a diseasespecific; Ankylosing Spondylitis quality of life (ASQoL) instruments and to explore its relationship to the clinical characteristics, disease activity, functional status, and radiographic severity. Methods: A total of 47 AS patients who fulfilled modified New York criteria were included. Disease activity, functional status, spinal mobility, and radiographic severity were assessed by Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Metrology Index (BASMI) and Bath AS Radiology Index (BASRI) respectively. SF-36 and ASQoL instruments evaluated Qol. Results: Physical health was more affected especially in patients with peripheral arthritis by SF-36 (p=0.008) and ASQoL (p=0.022) scores. Both SF-36 total and ASQoL scores correlated significantly with BASDAI (r = -0.329, p = 0.024 and r = 0.420, p = 0.003), BASFI (r = -0.399, p = 0.005 and r = 0.513, p=0.001) and BASMI (r = -0.382, p = 0.008 and r = 0.482, p= 0.001) respectively. Conclusion: QoL was impaired in AS patients with highest impact on physical health especially in association with peripheral arthritis. SF-36 and ASQol have a comparable achievement in the evaluation of QoL in AS patients and both physical function and spinal mobility were identified as predictors of poor QoL.

Sign in / Sign up

Export Citation Format

Share Document